Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia with Silodosin 8 mg Per Day. Issue 6 (23rd March 2020)

• Record Type: Journal Article
• Authors: Cihan, Ahmet; Kazaz, İlke Onur; Yıldırım, Ömer; Deliktaş, Hasan; Ongün, Şakir; Gül, Ümit; Şahin, Bahadır; Üre, İyimser; Özkara, Hamdi
• Is Part Of: Journal of sexual medicine. Volume 17:Issue 6(2020)
• Page Start: 1094
• Page End: 1100
• Publication Date: 2020-03-23
• Subjects: Silodosin -- Premature Ejaculation -- Benign Prostate Hyperplasia -- Erectile Function; Sexual disorders -- Periodicals; Sex -- Periodicals; Sexual health -- Periodicals; 616.69005
• DOI: 10.1016/j.jsxm.2020.02.023
• Languages: English
• ISSNs: 1743-6095

Abstract

Abstract: Background: Alpha-adrenergic antagonist treatment for benign prostatic hyperplasia (BPH) and drug-related sexual side effects are frequent in aging men. Aim: To investigate functional changes in erectile and ejaculatory aspects of male sexuality under Silodosin 8 mg per day treatment for BPH. Methods: Sexually active patients diagnosed with BPH and who initiated Silodosin treatment were the subjects of the study. The International Prostate Symptom Score, premature ejaculation patient profile (PEP-male) questionnaire, Sexual Health Inventory for Men (SHIM) questionnaire, and estimated intravaginal ejaculation latency time (IELT) values of the participants were used to evaluate sexual functions. Data evaluation was performed in 8 urology clinics retrospectively. Outcomes: Participant ratings for SHIM, PEP, and estimated IELT were the primary outcome measures in the study. Results: Among 187 recruited patients, data of 98 patients, who completed the trial period in the study, were eligible. The median age of the eligible participants who completed the trial period for 3 months was 59.5 years (range 45–82). 16 patients of 187 (8%) reported a desire for drug withdrawal for anejaculation during the recruitment period. 46 (46.9%) and 49 (50%) patients reported anejaculation in the first and third month of the treatment, respectively. De novo erectile dysfunction was noticed in 15 patients (15.3%). There was a significant increase in the estimated IELT of subjects in both the first ( P = .01) and third ( P = .002) month. SHIM-1 ( P = .008), SHIM-total ( P = .009), and PEP scores ( P = .008) were also improved in the third month of the treatment. Neither baseline patient characteristics nor changes in the International Prostate Symptom Score after treatment predicted final outcomes with multivariable analysis. The subgroup analysis of participants who reported "anejaculation" also revealed better outcomes compared with participants ejaculating naturally in the third month as per SHIM ratings. Clinical Implications: Despite several male patients having dry orgasms due to Silodosin-induced anejaculation, the majority experienced improved erectile function. Strengths & Limitations: The present study demonstrated pioneering results while investigating both erectile and ejaculatory dimensions of the male sexual function during Silodosin treatment for BPH. However, lack of partner evaluation, low follow-up rates, and lack of knowledge about reasons why subjects are lost to follow-up after drug initiation have limited our interpretation. Conclusion: Most patients using Silodosin 8 mg per day for BPH treatment experienced improvement in their erectile function, estimated IELT, and premature ejaculation profile in the third month of the treatment. Underlying mechanisms and reasons for individual differences necessitate further investigation.